Purple Biotech to Present CAPTN-3 Data at EORTC-NCI-AACR Symposium
Ticker: PPBT · Form: 6-K · Filed: Oct 10, 2024 · CIK: 1614744
Sentiment: neutral
Topics: biotech, drug-development, conference-presentation, pipeline-update
TL;DR
Purple Biotech presenting CAPTN-3 data next week at major cancer conference.
AI Summary
On October 10, 2024, Purple Biotech Ltd. announced it will present data for its Tri-Specific Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The symposium is scheduled to take place from October 21-25, 2024. This presentation highlights the company's progress in its novel antibody platform.
Why It Matters
The presentation of data for CAPTN-3 at a major oncology symposium could validate the platform's potential and attract further interest from the scientific and investment communities.
Risk Assessment
Risk Level: medium — The filing is a routine announcement of a scientific presentation, but the success of the presented data could significantly impact the company's future development and valuation.
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- CAPTN-3 (product) — Tri-Specific Antibody Platform
- EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (event) — Conference where data will be presented
- October 10, 2024 (date) — Date of press release
- October 21-25, 2024 (date) — Dates of the symposium
FAQ
What specific data will Purple Biotech present regarding CAPTN-3?
The filing states that data for the CAPTN-3 platform will be presented, but does not specify the exact nature or results of the data.
What is the significance of the EORTC-NCI-AACR Symposium?
It is a major symposium focused on molecular targets and cancer therapeutics, indicating a relevant and high-profile venue for presenting oncology-related data.
Has Purple Biotech presented data on CAPTN-3 before?
The filing does not provide information on previous presentations of CAPTN-3 data.
What is Purple Biotech's primary business focus?
Purple Biotech Ltd. is involved in pharmaceutical preparations, as indicated by its SIC code [2834].
When was Purple Biotech Ltd. previously known as Kitov Pharma?
The company was formerly known as Kitov Pharma Ltd. after a name change on January 25, 2018.
Filing Stats: 576 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-10-10 07:40:02
Filing Documents
- ea0217294-6k_purple.htm (6-K) — 16KB
- ea021729401ex99-1_purple.htm (EX-99.1) — 13KB
- 0001213900-24-086724.txt ( ) — 30KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. October 10, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2